Last reviewed · How we verify
Urokon (ACETRIZOIC ACID)
Acetrizoic Acid (Urokon) is a marketed drug with an unclear mechanism of action, primarily used in diagnostic imaging, facing competition from several off-patent same-class drugs such as diatrizoate and metrizoic acid. Its key strength lies in its continued market presence despite the lack of a fully understood mechanism, potentially benefiting from brand loyalty and established use. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased generic competition and revenue erosion.
At a glance
| Generic name | ACETRIZOIC ACID |
|---|---|
| Drug class | acetrizoic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Urokon CI brief — competitive landscape report
- Urokon updates RSS · CI watch RSS